Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Retinitis Pigmentosa (RP), Rod Cone Dystrophy
- Main trialPhase 1/2
- “This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.”In the company’s words, NCT07807111 on ClinicalTrials.gov
Other drugs for Retinitis Pigmentosa (RP)
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- UltevursenLaboratoires Thea · Phase 2
- OpCT-001BlueRock Therapeutics · Phase 1/2
- AAVB-081AAVantgarde Bio Srl · Phase 1/2
Coming up1
- Mar 2032Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Mar 2032 | Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026